New PCI programs cost billions, fail to improve timely access; olmesartan label change: potential for spruelike enteropathy; factor Xa inhibitor antidotes: evidence untestable in big trials?; sleep and CVD risk

New PCI programs cost billions, fail to improve timely access; olmesartan label change: potential for spruelike enteropathy; factor Xa inhibitor antidotes: evidence untestable in big trials?; sleep and CVD risk

Source: Radio TheHeart.org - July 12, 2013 Category: Cardiology Authors: theheart.org Tags: This week in cardiology from heartwire Source Type: podcasts